MRK vs ORCL: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Oracle Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
VS
Oracle Corporation · Technology
$175.08
+45.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
ORCL has more upside to fair value
(+45.0%).
MRK trades at a lower forward P/E
(22.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
ORCL |
| Current Price |
$114.27 |
$175.08 |
| Fair Value Estimate |
$118.00 |
$253.87 |
| Upside to Fair Value |
+3.3%
|
+45.0%
|
| Market Cap |
$282.2B |
$503.5B |
| Forward P/E |
22.4x
|
30.8x
|
| EV / EBITDA |
13.5x
|
21.4x
|
| Price / Sales |
4.3x
|
7.9x
|
| Price / FCF |
20.2x
|
-20.4x
|
| Revenue Growth YoY |
+5.0%
|
+21.7%
|
| Gross Margin |
81.9%
|
66.4%
|
| Operating Margin |
27.5%
|
30.8%
|
| Return on Equity |
5.6%
|
57.4%
|
| Dividend Yield |
2.91% |
0% |
| FCF Yield |
4.95%
|
—
|
| Analyst Consensus |
Overweight
|
Strong Buy
|
Investment Thesis
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Oracle Corporation is a leading enterprise software and cloud infrastructure provider with a strong legacy in database technology and a growing cloud business. The company benefits from a durable competitive moat supported by high insider ownership, experienced leadership, and a history of strategic acquisitions. Oracle's recent financials show robust revenue growth of 21.7% and earnings growth o…
Accumulation Zones
| Metric |
MRK |
ORCL |
| Zone Low |
$88.50 |
$190.40 |
| Zone High |
$100.30 |
$215.79 |
| In Buy Zone? |
No
|
Yes
|